Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:50:44.418Z.
Calculation as of: 2026-10-06T14:50:44.418Z.
Quote observation: 2026-10-06T14:50:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 026981202cadb8e73b6cbd63f18abfa8ffa74fea80ac6bbb32512047e0825b9f
PEG RATIO
N/A
Alamar Biosciences, Inc.
Market Cap
$2.40B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.40B | N/A |
| Liquidia Corporation (LQDA)vs › | $2.37B | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.42B | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.42B | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.32B | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.31B | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.26B | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.24B | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.58B | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
